NovoCure Ltd — Director's Dealing 2017

Feb 24, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Novocure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2017-02-22

Reporting Person: Kirson Eilon D. (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-02-22	Options to Buy Ordinary Shares	$7.15	A	273000	Acquired	2027-02-22	Ordinary Shares (273000)	Direct
2017-02-22	Restricted Stock Unit	$	A	109200	Acquired		Ordinary Shares (109200)	Direct

Footnotes

F1: Options to buy 273,000 ordinary shares will vest and become exercisable in equal installments on each of February 22, 2018, 2019, 2020 and 2021, subject to Mr. Kirson's continued employment through such dates.

F2: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share.

F3: One-third of these restricted stock units are scheduled to vest on each of February 22, 2018, February 22, 2019, and February 22, 2020, subject to Mr. Kirson's continued employment through such dates.